In adults with type 2 diabetes and existing heart disease, tirzepatide and dulaglutide show similar rates of stroke over nearly four years of follow-up, with no statistically significant difference...
Mechanism
Synthesis from 1 study
Both drugs work similarly to lower blood sugar and help people lose weight, which takes pressure off the blood vessels in the brain. Since neither drug does this job better than the other, they end up preventing strokes at about the same rate.
Most probable mechanism
Both drugs lower blood sugar and help people lose weight, which reduces strain on blood vessels in the brain. Since both drugs do this similarly, neither ends up being better at preventing strokes.
Both tirzepatide and dulaglutide activate GLP-1 and GIP receptors, leading to enhanced insulin secretion and reduced glucagon secretion.
This results in comparable reductions in fasting and postprandial blood glucose levels over the treatment period.
Both drugs induce similar degrees of body weight reduction through appetite suppression and delayed gastric emptying.
These combined metabolic improvements lead to comparable reductions in systemic inflammation, blood pressure, and endothelial dysfunction.
The similar magnitude of improvement in vascular risk factors results in comparable rates of cerebral perfusion stability and atherosclerotic plaque progression.
Evidence from Studies
Supporting (1)
Community contributions welcome
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.